Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. covers the month of June 2018. The report details a registered direct offering of ordinary shares and accompanying warrants entered into on June 14, 2018, with an expected closing date of June 19, 2018.
Key Financial Metrics
The filing focuses on a capital raise rather than operational performance metrics. Key figures include:
- Shares Offered: 5,316,457 ordinary shares.
- Warrants Offered: Up to 4,253,165 warrants to purchase ordinary shares.
- Offering Price: $3.95 per share and accompanying warrant.
- Warrant Exercise Price: $4.74 per ordinary share.
- Expected Net Proceeds: Approximately $19.9 million after deducting commissions and fees.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the dilution of existing shareholders due to the issuance of new ordinary shares and warrants. The company is increasing its cash liquidity through the expected net proceeds of $19.9 million. No comparative financial data for prior periods is provided in this specific filing.
Outlook, Risks, and Unusual Items
Management Commentary and Outlook: The offering is intended to raise capital for the company's operations. The warrants are exercisable beginning six months after issuance and expire five years from the date of issuance.
Risks and Contingencies: The closing of the offering is subject to customary closing conditions. The agreements include standard indemnification obligations and termination provisions. The filing notes that representations and warranties are limited to the specific agreements and dates.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received versus the estimated $19.9 million.
- Review the full text of the Placement Agreement and Securities Purchase Agreement (Exhibits 1.1 and 1.2) for specific covenants.
- Confirm the impact of the new share issuance on total outstanding shares and earnings per share.
- Monitor the exercise of warrants beginning six months post-issuance for potential future dilution.